Pacific Biosciences of California (PACB) stock closed at $1.24, down 3.88%

From Nasdaq: 2025-06-30 18:15:00

Pacific Biosciences of California (PACB) closed trading at $1.24, down -3.88%. Shares have risen by 33.86% in the past month, outperforming the Medical sector. Analysts predict an EPS of -$0.18 for the upcoming earnings report, with revenue estimated at $36.46 million. The Zacks Rank currently rates PACB as a #2 (Buy).

The Medical – Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 182, placing it in the bottom 27% of industries. The Zacks Industry Rank is calculated based on the average Zacks Rank of individual stocks. Top-rated industries outperform the bottom half by 2 to 1. Monitor these stock-influencing metrics on Zacks.com during upcoming trading sessions.

Zacks has identified a top semiconductor stock with immense growth potential. Despite being 1/9,000th the size of NVIDIA, this stock is positioned for significant growth due to strong earnings and an expanding customer base. With global semiconductor manufacturing projected to reach $803 billion by 2028, this stock has room to boom.



Read more at Nasdaq: Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know